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Breast-conserving therapy (BCT) for sporadic breast cancer has been widely accepted by surgeons and patients alike. While BCT
is associated with a higher risk of ipsilateral breast tumor recurrence (IBTR), it has not been shown to decrease overall survival
(OS) in comparison with mastectomy. Many women with a BRCA1/2 mutation opt for mastectomy instead of breast-conserving
measures at the time of a breast cancer diagnosis. In some cases, this is due to fear of aggressive disease, but to date, there have been
no studies oﬀering strong evidence that breast conservation should not be oﬀered to these women. BRCA1/2-associated breast
cancer has not been found to be more aggressive or resistant to treatment than comparable sporadic tumors, and no study has
shown an actual survival advantage for mastectomy in appropriately treated aﬀected mutation carriers. This paper reviews the
available literature for breast conservation and surgical decision making in BRCA1/2 mutation carriers.
1.Introduction
Knowledge about BRCA1 and BRCA2 and how patients with
mutations should be treated has been slow to develop since
the discovery of these genes in 1990 and 1994, respectively
[1, 2]. Many factors have limited collection of data on
this subject, such as availability of testing, expense, fear of
testing, and the small number of patients available for study.
The resultant lack of knowledge drives and sustains patient
anxiety, sometimes prompting them to select mastectomy in
hopes of a cure while sacriﬁcing cosmesis, body image, and
perhaps sexuality [3, 4]. In a 2003 study by van Oostrom
et al., 21 of 23 BRCA1/2 mutation carriers underwent
prophylactic mastectomy [5]. These patients reported a less
favorable body image, while 70% of them reported changes
in their sexual relationships. Prophylactic mastectomy has
been shown to reduce the risk of breast cancer incidence
or recurrence, but there is insuﬃcient data to support an
improvement in survival in aﬀected or unaﬀected carriers,
as discussed later [6–8]. Management decisions in BRCA1/2
carriers prophylactically or at the time of diagnosis of
an invasive cancer are complex. Patients will put diﬀerent
weights on diﬀerent aspects of treatment, some favoring
reducing the anxiety associated with surveillance and testing
and some favoring body image. There is insuﬃcient evidence
at this time to forgo surveillance and breast conservation
as viable options for BRCA1/2 mutation carriers, options
oﬀered to patients with most other forms of breast cancer.
2. Tumor Characteristics of
BRCA1/2-AssociatedBreastCancer
BRCA1/2 mutation carriers are known to have an increased
incidence of breast cancer and premalignant lesions [9–
13]. Histological diﬀerences in BRCA1-associated tumors
as compared to sporadic tumors have been well described.
BRCA2-associated tumors diﬀer from those of noncarriers
to a lesser extent. Invasive ductal carcinoma, NOS (not
otherwise speciﬁed) type, is the most common histologic2 International Journal of Breast Cancer
form of all hereditary breast cancers, including BRCA1-
and BRCA2-associated breast cancers [14]. Most BRCA1-
associated tumors have the basal-like phenotype and are
more frequently ER−,P R −,H e r 2 −, grade III, and of
the medullary subtype. The majority of studies show no
diﬀerence in tumor size or nodal status, factors known to
be more important for survival based on our current staging
of breast cancer [15–26]. The basal-like phenotype is rarely
found in BRCA2 breast cancers. BRCA2 breast carcinomas
tendtobeER+,PR+,Her2−,andhighergradethansporadic
age-matched controls [27] .T h eg r o w t hr a t eo fBRCA1/2-
associated breast tumors is not accelerated. Multivariate
analysis revealed that the apparent faster rate of growth in
BRCA1/2-associated tumors was found to be associated only
with a younger age at diagnosis and premenopausal status
[16, 28].
No study has shown that BRCA1/2-associated breast
cancer is more resistant to chemotherapy than are sporadic
breast cancer controls. This issue was speciﬁcally addressed
in a paper by Robson et al. in 2004, who found that the addi-
tion of chemotherapy negated any survival diﬀerence in the
BRCA1 mutation carriers compared with sporadic controls
[19]. Kriege et al. was similarly able to show that BRCA2-
associated tumors were more sensitive to anthracyclines
than sporadic tumors [29]. Both preclinical and clinical
studies have found that BRCA1-associated breast tumors are
sensitive to platinum agents and cyclophosphamide [30–34].
These studies are small but conﬁrm an increased complete
clinicalresponseinBRCA1/2-associatedcancerscomparedto
sporadic cases.
TherewasearlyconcernthatBRCA1/2-associatedtumors
were particularly radiosensitive [35], and because of the
role of these genes in DNA repair [35–37], that radiation
therapy may stimulate additional tumor formation. Studies
by Gaﬀney et al. and Pierce et al. found no evidence that
radiation therapy in this patient population is associated
with increased complications, recurrence, or with increased
tumorigenesis [24, 38].
Many women fear that BRCA1/2-associated cancers are
more aggressive than are sporadic tumors. The most impor-
tant question to answer here is whether there is a diﬀerence
in breast cancer speciﬁc survival (BCSS) or overall survival
(OS) between hereditary and sporadic tumors. Numerous
studies have addressed this issue, but they are limited by
small patient numbers and diﬀerences in treatment. To date,
we have found no studies that show a statistically signiﬁcant
diﬀerence in BCSS or OS after a breast cancer diagnosis
whenBRCA1/2carriersarecomparedwithmatchedsporadic
controls [15, 18–21, 23, 25, 38–41].
3. Breast Conservation Therapy in Affected
Mutation Carriers
There are limited studies evaluating breast conservation for
BRCA1/2 mutation carriers diagnosed with breast cancer
(aﬀected carriers). The information we seek to learn is in
regard to the risk of ipsilateral breast tumor recurrence
(IBTR), the risk of contralateral breast cancer (CBC),
breast cancer-speciﬁc survival (BCSS), and OS. In general,
the evidence available for evaluation is found in small
retrospective studies, most with relatively short followup.
Thesmallnumberofpatientsandlackoflong-termfollowup
are important concerns, as it is the number of events that
provides the needed information (Table 1). Ipsilateral or
contralateral disease can be new or recurrent disease. In the
ipsilateral breast, diﬀerent quadrants or diﬀerent histology
can be indicators of new primaries. Contralateral tumors,
invasive or noninvasive, are assumed to be new primaries.
Several reports by Pierce et al. about breast conservation
in BRCA1/2 mutation carriers stand out, as they directly
compare mastectomy to breast conserving therapy (BCT)
[40]. Their latest study, published in 2010, compares breast
conservation to mastectomy in 655 women with BRCA1/2
mutations diagnosed with breast cancer. 302 of these women
who underwent BCT and 353 who underwent unilateral
mastectomy were followed for 8.2 years and 8.9 years,
respectively. The estimated 15-year rate of IBTR was 23.5%
in the BCT group and 5.5% in the mastectomy group (P =
0.0001, HR 4.5). The ipsilateral recurrences were felt to
be second primaries in 16 of 23 (70%) cases. Two other
studies published in the last 10 years also show a diﬀerence
in IBTR between these two groups. Haﬀty et al. reported
ﬁndings of 22 patients with a BRCA1/2 mutation compared
to105womenwithoutthismutation,allofwhomunderwent
BCT [22]. All of the study participants were diagnosed with
breast cancer by the age of 42 and were followed for a
median of 12 years. These researchers reported an IBTR rate
of 49% in the mutation carriers compared to 21% in the
controls (P = 0.007). They similarly believed that these
ipsilateral recurrences were second primaries rather than
true recurrences. Garcia-Etienne et al. followed 54 BRCA1/2
patients and 162 sporadic controls treated with BCT with a
median followup of 4 years [23]. They reported a projected
10-year rate of IBTR of 27% in mutation carriers compared
to 4% in the sporadic controls, HR 3.9, P = 0.03 based
on 6 events in the carrier arm and 4 events in the control
arm. Criticisms of these studies include the observations
that there was a statistically signiﬁcant diﬀerence in the
mean age of the BRCA1/2 mutation carriers (33 years) and
the sporadic controls (37 years), (P = 0.001) and that
none of the mutation carriers underwent bilateral salpingo-
oophorectomy(BSO),nordidtheyreceivehormonaltherapy
(as compared to the 15% in the sporadic group, P = 0.05)
in the study by Haﬀty et al. [22]. Both studies by Pierce et al.
and Garcia-Etienne et al. project their data over longer time
points to estimate a diﬀerence in tumor recurrence [23, 40].
Several other informative studies have been published
reporting a rate of IBTR in patients undergoing BCT that
contradicts the ﬁndings reported above. An earlier study by
Pierce et al. revealed that there was no diﬀerence in IBTR
between 160 BRCA1/2 mutation carriers and 445 matched
controls all undergoing BCT with a median followup of 6.7
to 7.9 years [21]. Kirova et al. found no diﬀerence (P = 0.13)
in IBTR when they compared 27 BRCA1/2 mutation carriers
to 104 patients with a family history of breast cancer to 261
matchedcontrolswitha13.4yearfollowup[20].Kirovaatal.
found age to be the most signiﬁcant predictor of IBTR, withInternational Journal of Breast Cancer 3
Table 1: Outcomes of aﬀected BRCA1/2 mutation carriers.
Study Design Patients Followup IBTR BCSS OS
Pierce et al. [40]1 BCT = 302
Mast. = 353
8.2 to 8.9 years.
Data projected
to 15 years
BCT = 23.5%
Mast. = 5.5%
BCT = 91.7%
Mast. = 92.8%
P = 0.85
BCT = 87.3%
Mast. = 89.8%
P = 0.73
Haﬀty et al. [22]2 BRCA = 22
Sporadic = 105 12.7 years
BRCA = 41%
Sporadic = 19%
P = 0.007
Garcia-Etiene et al. [23]3 BRCA = 54
Sporadic = 162
4 years. Data
projected to 10
years
BRCA = 27%
Sporadic = 4%
P = 0.03
Pierce et al. [21]4 BRCA = 160
Sporadic = 445
6.7 to 7.9 years.
Data projected
to 15 years
BRCA = 24%
Sporadic = 17%
P = 0.19
Kirova et al. [20]5
BRCA = 27
Familial = 104
Sporadic = 261
13.4 years
BRCA = 45%
Familial = 31%
Sporadic = 24%
P = 0.33
Not signiﬁcant
at 20 years.
Actual rates not
reported.
Brekelmans et al. [25]6
BRCA = 326
Familial = 311
Sporadic = 759
4.3 to 5.1 years.
Data projected
to 10 years
BRCA = 20 to
25%
Familial = 6%
Sporadic = 5%
P = 0.001
BRCA = 62 to
68%
Familial = 70%
Sporadic = 59%
P = 0.17
BRCA = 50 to
60%
Familial = 66%
Sporadic = 55%
P = 0.32
Robson et al. [41]7
BRCA = 28
Sporadic = 277 10.3 years
BRCA = 22%
Sporadic = 7%
P = 0.25
BRCA = 72%
Sporadic = 87%
P = 0.02∗
BRCA = 66%
Sporadic = 81%
P = 0.05∗
Robson et al. [19]8
BRCA = 56
Sporadic = 440 9.7 years
BRCA1 = 63%
BRCA2 = 86%
Sporadic = 86%
P = < 0.0001∗∗
Abbreviations: IBTR: in-breast tumor recurrence; BCSS: breast cancer-speciﬁc survival; OS: overall survival; BCT: breast conserving therapy; Mast.:
mastectomy; BRCA: BRCA1/2 unless otherwise speciﬁed.
Study design: 1, BRCA1/2 carriers diagnosed with breast cancer treated with BCT or mastectomy. 2, BRCA1/2 carriers versus sporadic cancer diagnosis in
women <42 years of age undergoing BCT. 3, BRCA1/2-associated cancer matched with sporadic controls for age and year of surgery treated with BCT. 4,
BRCA1/2-associated cancer matched with sporadic controls treated with BCT. 5, BRCA1/2-associated cancer versus patients with family history of breast or
ovarian cancer versus sporadic controls matched for age and year of diagnosis treated with BCT. 6, breast cancer patients with versus without a family history
ofBRCA1/2mutationversussporadiccontrolsmatchedforageandyearofdiagnosistreatedwithBCTormastectomy.7,AshkenaziJewishwomenwithversus
without the BRCA1/2 founder mutation undergoing BCT. 8, Ashkenazi Jewish women with versus without the BRCA1/2 founder mutation undergoing BCT.
∗Reached signiﬁcance on univariate analysis but was lost on multivariate analysis.
∗∗This result was mitigated by and was no longer signiﬁcant after the addition of chemotherapy.
a relative risk (RR) of 1.05 for each decreasing year of age
(P = 0.01). Two other studies have reported no diﬀerence
in IBTR, but these diﬀer in their methods. Brekelmans et al.
reported no diﬀerence in IBTR in 226 patients with a family
historyofBRCA1/2comparedwith311patientswithafamily
history of breast cancer but testing negative for BRCA1/2
in the family, and compared to 759 patients with sporadic
breast cancer, with a mean duration of followup from 4.3
to 5.1 years [25]. Robson et al. also found no diﬀerence
in IBTR at 10 years when they compared 28 women of
AshkenazidescentwithBRCA1/2mutationsto277womenof
Ashkenazi descent without mutations, but they did ﬁnd age
<50 to be a statistically signiﬁcant risk of IBTR on univariate
analysis (16% versus 6%, P = 0.01) and on multivariate
analysis (RR 2.51, P = 0.01) [41]. Interestingly, it appears
that age at diagnosis rather than BRCA1/2 mutation status is
prognostically important in predicting IBTR [20, 22, 41].
With regard to the risk of contralateral breast cancer,
Pierce et al. reported no signiﬁcant diﬀerence in the rate
of CBC between the 302 BRCA1/2 mutation carriers who
underwent BCT and the 353 BRCA1/2 mutation carriers
who underwent unilateral mastectomy [40]. All of the other
studies we reviewed did reveal a diﬀerence in CBC ranging
from 1% to 11% in controls to 25% to 42% in mutation
carriers when BRCA1/2 mutation carriers were compared
to patients with familial, non-BRCA1/2-associated breast
cancer and/or sporadic controls [20–23, 25, 41, 42].
We found no study that showed a survival diﬀerence
when BCT was compared to mastectomy in BRCA1/2
mutation carriers or when BCT was compared in BRCA1/2
mutation carriers and familial, non-BRCA1/2-associated
breast cancer and/or sporadic controls [19–21, 23, 25, 40,
41]. Survival is inﬂuenced by stage of disease at diagnosis,
tumor characteristics, and treatment. Triple-negative tumors4 International Journal of Breast Cancer
appeartoinﬂuencesurvival;therefore,themixofBRCA1and
BRCA2 cases in a given paper may also inﬂuence survival
data. Because of the small patient population reported in
these papers, we are not able to separately evaluate BRCA1
and BRCA2 for IBTR, CBC, BCSS, and OS in triple-negative
breast cancer. Due to the increased risk of IBTR and the
elevated risk of CBC in BRCA1/2 mutation carriers, risk-
reducing strategies such as BSO or the use of tamoxifen, for
those with ER-positive tumors, should be employed as they
have been shown to reduce breast cancer recurrence [43].
4. Risk Reduction withBilateral Prophylactic
Mastectomy (BPM), Bilateral
Salpingo-Oophorectomy (BSO), and
Tamoxifen in UnaffectedMutationCarriers
Many women elect to undergo bilateral prophylactic mas-
tectomy (BPM) sometime after learning of their BRCA1/2
mutation status. The reasons for this decision are complex
andwillbediscussedinthenextsection.ThebeneﬁtsofBPM
inunaﬀectedmutationcarriersareknownprimarilythrough
the results of a few published studies. The Prose study group
has published two papers that detail the beneﬁts of BPM.
Their ﬁrst paper, published in 2004, followed 483 women
with a BRCA1/2 mutation for a mean of 6.4 years [6]. They
reported a 1.9% prevalence of breast cancer in 105 women
who underwent BPM compared with 48.7% of 378 women
undergoing surveillance only. Women who had undergone
prophylactic BSO were excluded. Their followup study with
additional patients, reported in 2010 by Domchek et al. with
three years of prospective followup, also noted a diﬀerence
in breast cancer diagnosis, from 0% in the BPM group to
7% in the non-BPM group [44]. A study predating these, by
Meijers-Heijboeretal.[7]prospectivelyfollowed139women
with BRCA1/2 mutations for a mean of 2.9 to 3 years [7].
76 of these women underwent BPM and were found to have
no breast cancers diagnosed, compared with 8 of 63 women
(12.7%) who underwent screening only (P = 0.003). The
authors do not provide data related to survival diﬀerences
in these papers, as the number of events is too small, as is the
length of followup [6, 7, 44].
The preventive beneﬁt of prophylactic BSO does appear
toreducetheprevalenceofbreastcanceraswellastoimprove
BCSS and to improve OS in premenopausal BRCA1/2 muta-
tion carriers [25, 40, 44]. Therefore serious consideration
should be given to this preventive measure in women after
they complete their families, ideally between 35 and 40
years or individualized based on the earliest age of ovarian
cancer diagnosis in the family. Women who are BRCA1/2
mutation carriers and choose not to undergo prophylactic
BSO may wish to consider the use of tamoxifen, as it
has been shown to reduce breast cancer incidence in that
group [43, 45]. For young women with BRCA1/2 mutations
or who are otherwise at high risk for breast cancer, the
current American Cancer Society guidelines recommend the
inclusion of screening MRI, which has been shown in several
studies to have increased sensitivity (79.5% to 91%) for T2
or smaller breast cancer compared to mammography with or
without the addition of ultrasound (33% to 50%) [46–49].
No recommendations exist for surveillance after a diagnosis
of breast cancer in this population.
5.SurgicalDecisionsinAffectedandUnaffected
BRCA1/2 Mutation Carriers
Several studies have addressed surgical decision making
in unaﬀected BRCA1 and BRCA2 mutation carriers. The
reported proportions of women who adopt risk-reducing
bilateral mastectomy versus intense surveillance are highly
variable.Alimitedreviewoftheliteraturerevealedsixstudies
that analyzed the utilization of risk-reducing mastectomy
versus surveillance in unaﬀected women identiﬁed as carry-
ing a BRCA1 or BRCA2 gene mutation [50–55].
In a study of 279 adult male and female members of
families with an identiﬁed BRCA1 gene mutation from a
registry maintained by the Creighton University Hereditary
Cancer Institute, 43% requested BRCA1 test results [50]. Of
those tested for the previously identiﬁed familial mutation,
46% (53 of 115 electing to receive results) were mutation
carriers. Among the unaﬀected BRCA1 mutation carriers
with no previous prophylactic surgery, 17% (2 of 12)
intended to have risk-reducing bilateral mastectomy, but
none had actually undergone surgery 1 month after BRCA
testing. Likewise, Botkin et al. documented a low rate of
risk-reducing bilateral mastectomy among 37 unaﬀected
BRCA1/2 mutation carriers [51]. At 2 years after testing, no
women had undergone mastectomy for cancer prophylaxis;
however, some reported that they were strongly considering
surgery. Of those women, 2 of the 20 women in the younger
(25–39 years) age group stated that they were considering
this procedure, and 2 of the 12 women in the older (40 years
and older) carrier group stated that they were considering
it. In addition, Botkin et al. reported an increase in the
utilization of mammography and self-breast examination
among unaﬀected carrier females who did not chose surgery.
In contrast, three studies demonstrated a larger number
of unaﬀected BRCA carriers who elected to undergo BPM.
In a Rotterdam-based study of unaﬀected women with
an identiﬁed mutation who were eligible for prophylactic
surgery, 51% (35 of 68 women) opted for risk-reducing
bilateral mastectomy [52]. The authors reported that of
these women, there was a tendency towards mastectomy at
younger ages; most were between 30 and 44 years old. Also,
the decision to undergo BPM was often made within the ﬁrst
year following receipt of their BRCA test results. Lodder et al.
found that 53.8% of mutation carriers (14 of 26 unaﬀected
BRCAcarriers)underwentBPMoneyearaftergenetictesting
[53]. They reported that often the decision for preventive
surgery was made before the disclosure of test results for
women who had a 50% ap r i o r irisk of carrying a known
familial BRCA mutation. Lastly, in the largest prospective
study of 251 individuals with conﬁrmed BRCA mutations at
Memorial Sloan-Kettering Cancer Center, 29 of 194 women
(14.9%) who had breast tissue at risk at the time they
received genetic test results underwent bilateral mastectomy
for cancer prophylaxis within a median of 5.3 months afterInternational Journal of Breast Cancer 5
receiving results [54]. Twenty of the 233 BRCA carriers had
previously elected BPM based on family history alone. Data
presented at the Facing Our Risk of Cancer Empowered
Joining FORCEs conference in 2007 by Dr. Steve Narod and
published in 2008 by Metcalf et al. discussed international
variation in the decision to undergo prophylactic surgeries
[55, 56]. Narod introduced data from an ongoing study
of 8,058 known BRCA1 or BRCA2 mutation carriers from
11 countries. Within a four-year followup period, 36%
of unaﬀected carriers from the United States chose BPM.
Overall 248 (18%) of the 1382 unaﬀected carriers from all
countries chose prophylactic mastectomy.
Many BRCA1/2 mutation carriers diagnosed with breast
cancer (aﬀected carriers) opt for bilateral mastectomy rather
than BCT for initial treatment of disease. Therefore, hered-
itary cancer risk assessment at the time of diagnosis may
signiﬁcantly aﬀect a woman’s treatment decisions. Four
studies investigating surgical decision making in BRCA
carriers at breast cancer diagnosis were identiﬁed through
our literature search. Weitzel et al. found that 7 of 32 (22%)
women with a newly diagnosed breast cancer carried a
deleterious BRCA mutation [57]. All 7 of these women opted
for contralateral prophylactic mastectomy. In a prospective
study of 194 newly diagnosed breast cancer patients at
Lombardi Cancer Center, 31 women were identiﬁed as
carrying a BRCA mutation [58]. Forty-eight percent of these
carriers chose bilateral mastectomy as the deﬁnitive surgical
treatment for their breast cancer. Evans et al. identiﬁed
20 of 70 newly diagnosed breast cancer patients younger
t h a n5 0a sBRCA mutation carriers [59]. Four of these
women were aware of their genetic status at the time
of diagnosis and three elected bilateral mastectomy. Four
women were told of their mutation status within four weeks
of diagnosis. Of these, two opted for bilateral mastectomy
although one chose delayed contralateral mastectomy. The
remaining 12 mutation carriers were told of their genetic
status 3–36 months after diagnosis. Of these 12 women, one
opted for contralateral mastectomy. In the data presented by
Narod, the percentage of breast cancer survivors choosing
contralateral prophylactic mastectomy was outlined for 8
countries, with Israel showing the largest proportion of
prophylactic surgery (52%) followed by the United States
(49%), Canada (28%), France (20%), Austria (16%), Italy
(6%), and Poland (4%) [55].
For women and families who are found to carry a variant
of uncertain clinical signiﬁcance (VUS) in either BRCA1 or
BRCA2,screeningrecommendationsareoﬀeredaccordingto
personal and family history of cancer. There are few reports
documenting prophylactic surgery and screening behaviors
of individuals whose BRCA test results revealed a VUS,
which is most likely a reﬂection of medical management
guidelines published by the National Comprehensive Cancer
Network, the National Society of Genetic Counselors, and
the American Society of Clinical Oncology [60–62]. Surgical
decision making in the context of a BRCA VUS is also based
on personal and family history, as a VUS is uninformative
with respect to cancer risk. Those individuals with classic
hereditary breast-ovarian cancer syndrome may elect risk-
reducing surgery based on family history alone and their
own level of concern and anxiety. There are no published
data to support prophylactic surgery in the equivocal risk
population based on a BRCA VUS. Weitzel et al. reported
that one of three women identiﬁed with a VUS at the time of
a breast cancer diagnosis elected risk-reducing mastectomy
eventhoughtheywerecounseledthattheresultsoftheBRCA
sequencing were uninformative [57]. Those patients cited
fear of cancer and uncertainty associated with the ﬁnding of
a VUS as reasons for pursuing mastectomy.
Although the risk of breast cancer in other hereditary
cancer predisposition syndromes, such as Li-Fraumeni and
Cowden syndrome, is known to be signiﬁcantly elevated
above that in the general population (as high as 50%),
the eﬃcacy of appropriate medical management and cancer
prevention options for these patients has not been widely
studied; therefore, they are based mainly on expert opinion.
Current recommendations suggest discussing the option of
prophylactic mastectomy on a case-by-case basis, including
a detailed discussion reviewing the risk reduction beneﬁt,
cancer risks, and available reconstruction options [60].
Many factors contribute to the decision-making process
with respect to increased surveillance and prophylactic
surgeries for mutation carriers. The process is complex and
can have a strong psychological impact, a subject that has
also been extensively explored in the literature. Unaﬀected
BRCA carriers who elect prophylactic mastectomy often
report a higher perceived risk of developing breast cancer,
higher levels of cancer-related worry, and higher levels of
cancer-related distress than those who opt for surveillance.
Individuals choosing risk-reducing surgery may also be
aware of the hereditary nature of cancer in the family for
a longer period of time and report a greater number of
relatives aﬀectedwithbreastandovariancancerinthefamily,
resulting in more ﬁrst-hand experience with cancer and
making them more apt to consider surgery for risk reduction
[53, 63, 64]. Many studies have shown that women who
choose bilateral mastectomy tend to be younger (between
30 and 43 years of age), have young children, and have a
fear of leaving behind young children [52, 53, 64]. Surgical
risk reduction is also sought with the intent to prolong life,
the relief associated with a signiﬁcant reduction in cancer
risk,thenegativepathologiccharacteristicsofthetumor,and
the desire to avoid further surgery at a later stage of cancer
[53, 54, 59].
In contrast, BRCA mutation carriers who opt for
surveillance cite reasons relating to possible dissatisfaction
with general body image following mastectomy, the sexual
relationship, and their trust in surveillance modalities.
Women who opt for surveillance report being worried that
they will not feel feminine, will not feel sexually attractive,
and will have problems in the intimate relationship fol-
lowing mastectomy [53]. Unaﬀected BRCA carriers opting
for surveillance speciﬁcally say that prophylactic bilateral
mastectomy is too drastic an intervention and that they
are reluctant to have healthy breast tissue removed. In
addition, these women feel that they have time to explore
the options of surgical risk reduction while undergoing
surveillance. However, it is recognized that these attitudes
may change over time, especially after a longer period of6 International Journal of Breast Cancer
intensive breast surveillance and failure to comply with
followup recommendations [64].
The majority of women who elect risk-reducing mastec-
tomy are satisﬁed with their decision [65]. Those women
who do regret undergoing mastectomy report that the dis-
satisfactionstemsfromsurgerycomplications,poorcosmetic
outcome, residual pain, fear that reconstruction will impede
breast cancer detection, poor self-image, sexual dysfunction,
lack of psychological support after surgery, and the fact that
the subject of mastectomy was initiated by the physician
rather than by the patient herself [53, 65–67]. With regard
to the latter, many studies have illustrated that physician
recommendations are an important determinant of surgical
decisions, especially for women with a newly diagnosed
breast cancer [58].
The decision to undergo prophylactic mastectomy for
both unaﬀected BRCA mutation carriers and newly diag-
nosed carriers is a major, irreversible decision. Although a
minority of BRCA c a r r i e r sc h o o s ep r o p h y l a c t i cm a s t e c t o m y
over intense surveillance,the majority of womenwho choose
mastectomy are satisﬁed with their decision, report reduced
cancer-related anxiety about developing breast cancer fol-
lowing surgery, and report favorable psychosocial outcomes.
6. Conclusions
It is clear that women with BRCA1/2 mutations have a
much higher risk of developing breast cancer than the 12.5%
lifetime risk of the general population [68]. The risk of
developing breast cancer by the age of 70 for carriers of
BRCA1 is 57% to 65%, while the risk in BRCA2 carriers
is slightly lower, at 45% to 49%, based on the ﬁndings of
two recent metaanalyses [12, 13]. Many women choose to
undergo bilateral prophylactic mastectomy, which has been
shown to reduce the incidence of breast cancer in these
patients, after learning that they are mutation carriers [6–
8, 44]. Reduced BCSS in unaﬀected carriers is assumed
althoughit has not been objectively quantiﬁed because of the
shortdurationoffollowupandlownumberofeventsinthese
studies.
It appears that many women diagnosed with an inva-
sive breast cancer associated with a BRCA1/2 mutation
or a strong family history choose mastectomy as their
deﬁnitive surgical therapy in lieu of breast conservation
with irradiation. Other authors have reported the increased
use of mastectomy over breast conservation in the general
population with sporadic breast cancers for a variety of
r e a s o n sa sw e l l[ 69, 70]. It has been shown that aﬀected
carriers undergoing mastectomy rather than BCT have a
lower incidence of IBTR [19–23, 25, 40, 41]. Perhaps there
is the beneﬁt of “peace of mind” that comes with the reduced
IBTR that those treated with BCT, and therefore, still subject
to screenings and biopsies, do not have.
It has not been established that mastectomy at the time
of a cancer diagnosis is the best therapeutic option, as
several studies have shown that the BCSS and/or the OS
in BRCA1/2 is no diﬀerent than that of sporadic cancers
[15, 18, 39, 71, 72]. Studies evaluating breast conservation
for the treatment of invasive disease in BRCA1/2 carriers
compared to that in sporadic controls reveal mixed results
related to IBTR, but none have shown a diﬀerence in
BCSS and/or OS [20, 22, 23, 25, 41, 71]. One study that
compared mastectomy to breast conservation in BRCA1/2
carriers noted an increased IBTR but no diﬀerence in OS
[40]. For BRCA1/2 mutation carriers who opt for BCT,
risk-reducing strategies, such as the use of tamoxifen (for
ER+ tumors) or BSO, are appropriate, as they appear to
reduce the risk of IBTR and CBC [21, 22, 40, 43, 45]. No
individual recommendations can be made for BRCA1 apart
from BRCA2 mutation carriers, as most studies consider
them together and have thus far had inadequate numbers to
segregate the two despite their histologic diﬀerences and the
proposeddiﬀerencesincellfunctionthatBRCA1andBRCA2
control [73].
At this time, the use of breast-conserving therapy in
patients who are mutation carriers or who have a very
strong family history for breast cancer should be handled
on a case-by-case basis. Patients should be evaluated and
informed about the current existing data and outcomes
before an ultimate surgical decision is made. Consultation
with a genetic counselor may be of beneﬁt in helping the
patient make an informed decision.
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